Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | NPY4R | P50391 | 3/20 | 0.54 |
| ▸ | FPR2 | P25090 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | AVPR2 | P30518 | 4/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12870952 | 0.96 | TGM2 (0.60) | TGM2NPY4RFPR2MEN1USP2 | |
| SCHEMBL18732968 | 0.94 | TGM2 (0.61) | TGM2NPY4RFPR2MEN1USP2 | |
| SCHEMBL13114579 | 0.94 | TGM2 (0.58) | TGM2NPY4RFPR2MEN1USP2 | |
| SCHEMBL3504540 | 0.92 | TGM2 (0.60) | TGM2NPY4RFPR2MEN1USP2 | |
| SCHEMBL17126766 | 0.92 | TGM2 (0.60) | TGM2NPY4RFPR2MEN1USP2 | |
| SCHEMBL18087519 | 0.91 | TGM2 (0.62) | TGM2NPY4RFPR2MEN1USP2 | |
| SCHEMBL13895487 | 0.90 | TGM2 (0.57) | TGM2NPY4RFPR2MEN1USP2 | |
| Hydrochloric Acid SCHEMBL13736180 | 0.89 | TGM2 (0.57) | TGM2NPY4RFPR2MEN1USP2 | |
| SCHEMBL18067135 | 0.88 | TGM2 (0.60) | TGM2NPY4RFPR2MEN1USP2 | |
| SCHEMBL13135018 | 0.88 | TGM2 (0.54) | TGM2NPY4RFPR2MEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100252433-A1 | NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSES | NATIONAL SCIENCE FOUNDATION | 2010-10-07 | — | — | US | disclosed |
| US-20100252433-A1 | NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSES | NATIONAL SCIENCE FOUNDATION | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100252433-A1 | NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSES | PTMS, CHAMP1, RAB5IF | TGM2 1593/4885NPY4R 4263/4885FPR2 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.